Biotech


  • Gene editing
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The FDA just approved the first CRISPR drug. Here’s what’s next in gene editing.

    A look at the fast-evolving pipeline for gene editing therapies.

    By Dec. 8, 2023
  • Shankar Narayanan, CEO, Real Chemistry
    Image attribution tooltip
    Permission granted by Real Chemistry
    Image attribution tooltip

    Real Chemistry’s CEO on biopharma’s outlook in 2024

    Shankar Narayanan, CEO of marketing consulting firm Real Chemistry, weighs in on where the industry is headed in the New Year.

    By Dec. 7, 2023
  • women's health Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Women's health

    As women’s health investments explode, major opportunities for growth remain.

    By PharmaVoice staff
  • A CRISPR Therapeutics sign is seen above a door to an office building
    Image attribution tooltip
    Permission granted by CRISPR Therapeutics
    Image attribution tooltip

    CRISPR eyes autoimmune disease in revamp of cell therapy plans

    The gene editing biotech is shelving two of its most advanced cancer drugs, and joining a growing group of companies exploring cell-based medicines for inflammatory diseases like lupus.

    By Ben Fidler • Dec. 6, 2023
  • A window with the logo for Amicus Therapeutics.
    Image attribution tooltip
    Amicus Therapeutics
    Image attribution tooltip

    BIO names longtime Amicus head John Crowley as new CEO

    Crowley, a rare disease advocate who led Amicus for nearly two decades, will take the reins as the industry group seeks to challenge Medicare’s new drug pricing powers.

    By Jonathan Gardner • Dec. 5, 2023
  • dollar sign airplane
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The weight loss market looks unstoppable. How high could it go?

    Market expectations for obesity drugs are soaring and competition is heating up. But hitting the heights will require overcoming payer and other issues.

    By Kelly Bilodeau • Dec. 4, 2023
  • tangled knot between two businessmen walking a tightrope
    Image attribution tooltip
    Cemile Bingol via Getty Images
    Image attribution tooltip

    The fortunes and flops of pharma M&A

    Hindsight offers a better perspective on why some deals are fruitful and others fail.

    By Alexandra Pecci • Dec. 4, 2023
  • Portrait of John Mulligan, chief executive officer of Bonum.
    Image attribution tooltip
    Permission granted by Bonum Therapeutics
    Image attribution tooltip

    How to succeed in biotech: A serial entrepreneur’s tips for surviving tough times

    John Mulligan, founder of biotechs like Good Therapeutics and Bonum Therapeutics, discusses how biotechs can thrive when the market is against them.

    By Nov. 30, 2023
  • Header image for "Creating a Compelling IPO Roadshow Presentation"
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Biopharma’s top 5 IPOs of 2023 (so far)

    Despite one major outlier, 2023’s IPOs haven’t hit the heights of the past three years.

    By Alexandra Pecci • Nov. 28, 2023
  • alcohol bottles illustration
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As alcohol-related deaths climb, new drugs could curb the urge to drink

    A drug developed by Kinnov Therapeutics halved alcohol consumption in heavy drinkers in a mid-stage study.

    By Kelly Bilodeau • Nov. 27, 2023
  • body muscle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Biohaven wants to muscle in on the Ozempic craze with a competing class of drugs

    Biohaven and other companies are aiming to develop meds with a different mechanism of action that trim the waistline while building lean tissue.

    By Kelly Bilodeau • Nov. 20, 2023
  • man in dark tunnel
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    ​​A startling drop in U.S. life expectancy — and how pharma could help turn the tide

    The recently observed dip was particularly acute for men, who now live an average of 5.8 fewer years than women.

    By Nov. 17, 2023
  • Dr. Paul Moss, deputy head, College of Medical and Dental Sciences, Professor of Haematology, University of Birmingham
    Image attribution tooltip
    Permission granted by AstraZeneca/U. of Birmingham
    Image attribution tooltip
    Q&A

    AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?

    Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.

    By Nov. 16, 2023
  • Genomics DNA
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    The power of genomics-based healthcare remains largely untapped

    23andMe co-founder and CEO Anne Wojcicki discusses ways the industry could integrate genomics into healthcare.

    By Alexandra Pecci • Nov. 15, 2023
  • Lindsay Pino, co-founder, chief technology officer, Talus Bio
    Image attribution tooltip
    Permission granted by Talus Bio
    Image attribution tooltip
    Biotech Spotlight

    A biotech tackles drug discovery with transcription factor know-how

    Talus Bio, which developed a platform to map transcription factors, has a lead cancer candidate in the works and consults with other industry players in the complicated biology.

    By Nov. 15, 2023
  • A photograph of a Sarepta building in Boston, MA
    Image attribution tooltip
    Courtesy of Sarepta
    Image attribution tooltip

    Can Sarepta’s Duchenne gene therapy still deliver on its promise?

    For Sarepta — and DMD patients — there’s a lot riding on the treatment’s next steps.

    By Kelly Bilodeau • Nov. 14, 2023
  • moquito art
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Humans can’t shake the mosquito threat. Here’s what pharma has in the pipeline.

    The arsenal against the world’s deadliest creature is growing and a universal vaccine is in the works.

    By Kelly Bilodeau • Nov. 13, 2023
  • Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes
    Image attribution tooltip

    stock.adobe.com/master1305

    Image attribution tooltip
    Sponsored by ClinicalMind

    Optimizing KOL engagement and technology utilization in 2024

    What if your advisory solution was a skillful blend of innovative tech, medical communications specialists, high-touch client service, and a flexible contract?

    Nov. 13, 2023
  • ceo pay
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    5 of the best paid biopharma CEOs

    As revenue growth remained high last year, so did biopharma CEO pay in the U.S.

    By Alexandra Pecci • Nov. 10, 2023
  • Jean Jacques Bienaime headshot
    Image attribution tooltip
    Permission granted by BioMarin
    Image attribution tooltip
    Making Moves

    Does BioMarin’s CEO shuffle signal bigger changes ahead?

    With its long-time CEO on the way out, the rare disease biotech has seen an activist investor grow its stake.

    By Nov. 9, 2023
  • A scale is foregrounded against the sky.
    Image attribution tooltip
    zennie via Getty Images
    Image attribution tooltip

    How pharma leaders talk about ethics in a highly criticized industry

    The maze of ethical issues in biopharma can confound even the wiliest executive. How do some leaders get by?

    By Nov. 9, 2023
  • A sickle cell and normal blood cells are seen in red against a blue background in this colorized microscope image.
    Image attribution tooltip

    Janice Haney Carr/CDC/Sickle Cell Foundation of Georgia/AP

    Image attribution tooltip
    Deep Dive

    What if a CRISPR cure isn’t such an easy choice?

    A gene editing therapy developed by Vertex Pharmaceuticals and CRISPR Therapeutics can mute sickle cell disease’s most damaging symptoms. Yet treatment may not be as simple as its dramatic benefit makes it seem.

    By Ned Pagliarulo , Nov. 9, 2023
  • FluMist
    Image attribution tooltip
    Mario Tama / Getty via Getty Images
    Image attribution tooltip

    An at-home flu vaccine? If approved, it could open the door to more DIY options

    A new way to administer vaccines at home could help AstraZeneca reach a wider market for FluMist, the nasal influenza vaccine.

    By Kelly Bilodeau • Nov. 8, 2023
  • Sarah Boyce, CEO and president, Avidity Biosciences
    Image attribution tooltip
    Permission granted by Avidity
    Image attribution tooltip
    Biotech Spotlight

    A new delivery method muscling its way into the RNA space

    With an AOC platform targeting muscle diseases, Avidity Biosciences hopes to break open the possibilities of RNA.

    By Kelly Bilodeau • Nov. 8, 2023
  • Anne Wojcicki red carpet
    Image attribution tooltip
    Dia Dipasupil via Getty Images
    Image attribution tooltip
    Q&A

    23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’

    23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.  

    By Alexandra Pecci • Nov. 7, 2023
  • Arthur Caplan, professor of bioethics and founding head of the Division of Medical Ethics, NYU’s Grossman School of Medicine
    Image attribution tooltip
    Permission granted by NYU
    Image attribution tooltip
    Opinion

    The thorniest questions facing pharma, according to a leading bioethicist

    Bioethics guru Arthur Caplan of NYU gives his outspoken and frank opinion on the industry’s minefield of ethical challenges.

    By Nov. 6, 2023